Appendix 2: Supplementary figures [posted as supplied by author]

WEB APPENDIX FIGURE LEGEND

- **Figure A1.** Stent type and risk of target vessel revascularization in trial with clopidogrel duration of at least 6 months. The numbers represents rate ratio (RR) and 95% credibility intervals (CrI). BMS= Bare Metal Stent; Ref= Reference.
- **Figure A2.** Stent type and risk of target lesion revascularization in trial with clopidogrel duration of at least 6 months. The numbers represents rate ratio (RR) and 95% credibility intervals (CrI). BMS= Bare Metal Stent; Ref= Reference.
- **Figure A3.** Stent type and risk of death in trial with clopidogrel duration of at least 6 months.

 The numbers represents rate ratio (RR) and 95% credibility intervals (CrI). BMS=

 Bare Metal Stent; Ref= Reference.
- **Figure A4.** Stent type and risk of myocardial infarction in trial with clopidogrel duration of at least 6 months. The numbers represents rate ratio (RR) and 95% credibility intervals (CrI). BMS= Bare Metal Stent; Ref= Reference.
- **Figure A5.** Stent type and risk of any stent thrombosis in trial with clopidogrel duration of at least 6 months. The numbers represents rate ratio (RR) and 95% credibility intervals (CrI). BMS= Bare Metal Stent; Ref= Reference.
- **Figure A6.** Stent type and risk of ARC defined definite or probable stent thrombosis in trial with clopidogrel duration of at least 6 months. The numbers represents rate ratio (RR) and 95% credibility intervals (CrI). BMS= Bare Metal Stent; Ref= Reference.
- **Figure A7.** Stent type and risk of ARC defined definite stent thrombosis in trial with clopidogrel duration of at least 6 months. The numbers represents rate ratio (RR) and 95% credibility intervals (CrI). BMS= Bare Metal Stent; Ref= Reference.

- **Figure A8.** Stent type and risk of target vessel revascularization in a sensitivity analysis including the Zotarolimus-Resolute trials (target vessel/lesion failure substituted for TVR for the Resolute trials). The numbers represents rate ratio (RR) and 95% credibility intervals (CrI). BMS= Bare Metal Stent; Ref= Reference.
- **Figure B1.** Q-Q plot for the network of all trials for the outcome of target vessel revascularization.
- **Figure B2.** Q-Q plot for the network of all trials for the outcome of target lesion revascularization.
- **Figure B3.** Q-Q plot for the network of all trials for the outcome of death.
- Figure B4. Q-Q plot for the network of all trials for the outcome of myocardial infarction.
- Figure B5. Q-Q plot for the network of all trials for the outcome of any stent thrombosis.
- **Figure B6.** Q-Q plot for the network of all trials for the outcome of ARC defined definite or probable stent thrombosis.
- **Figure B7.** Q-Q plot for the network of all trials for the outcome of ARC defined definite stent thrombosis.

Figure A1
Outcome: TVR

Outcome: TVR Treatment	Control	Treatment	Control	Rate Ratio	95%	Crl
BMS (Ref)						
	Sirolimus	-		0.38	0.28	0.49
	Paclitaxel	-		0.48	0.35	0.65
	Everolimus			0.31	0.17	0.49
	Zotarolimus	_	_	0.65	0.40	1.10
Sirolimus (Ref)						
	Paclitaxel		-	1.28	0.99	1.68
	Everolimus	-	_	0.83	0.51	1.21
	Zotarolimus		-	1.74	1.14	2.80
Paclitaxel (Ref)						
	Everolimus		_	0.65	0.39	0.94
	Zotarolimus		—	1.36	0.86	2.19
Everolimus (Ref)						
	Zotarolimus		-	2.11	1.23	4.13
	0.10	1	.00	10.00		
		RR (95% Crl)			

Figure A2
Outcome: TLR

Treatment	Control	Treatment	Control	Rate Ratio	95%	Crl
BMS (Ref)						
	Sirolimus	-		0.34	0.22	0.47
	Paclitaxel	-		0.48	0.33	0.70
	Everolimus	-		0.27	0.13	0.48
	Zotarolimus		-	0.90	0.46	1.77
Sirolimus (Ref)						
	Paclitaxel		-	1.45	1.07	2.10
	Everolimus		•	0.81	0.43	1.34
	Zotarolimus		-	2.71	1.56	5.17
Paclitaxel (Ref)						
	Everolimus		_	0.56	0.27	0.93
	Zotarolimus			1.87	1.04	3.41
Everolimus (Re	rf)					
	Zotarolimus		-	3.33	1.61	8.62
		0.10	1.00	10.00		
		RF	R (95% Crl)			

Figure A3

Outcome: Death Treatment	Control	Treatment	Control	Rate	Ratio	95%	Crl
BMS (Ref)			ı				
	Sirolimus	_			0.95	0.66	1.25
	Paclitaxel	_	_		0.89	0.62	1.27
	Everolimus		_		0.81	0.44	1.36
	Zotarolimus		-		1.17	0.54	2.11
Sirolimus (Ref)							
	Paclitaxel	_	_		0.94	0.72	1.33
	Everolimus		 		0.85	0.50	1.42
	Zotarolimus	_	-		1.23	0.63	2.10
Paclitaxel (Ref)							
	Everolimus		_		0.90	0.51	1.44
	Zotarolimus		—		1.32	0.62	2.32
Everolimus (Ref)							
	Zotarolimus	_	•		1.46	0.69	3.05
	0.10	1	.00	10.00			
		RR (9	5% Crl)				

Figure A4
Outcome: MI

Treatment	Control	Treatment	Control	Rate Ratio	95%	Crl
BMS (Ref)			1			
	Sirolimus	-	_	0.73	0.50	1.10
	Paclitaxel	-	-	0.87	0.58	1.30
	Everolimus	-	_	0.55	0.21	1.15
	Zotarolimus		*	2.60	0.92	6.99
Sirolimus (Ref)					
	Paclitaxel	_	-	1.18	0.80	1.72
	Everolimus	-	_	0.76	0.29	1.38
	Zotarolimus			3.49	1.10	8.83
Paclitaxel (Ref	7)					
	Everolimus		_	0.65	0.26	1.14
	Zotarolimus	-	*	3.03	0.87	7.65
Everolimus (R	ef)					
	Zotarolimus		•	4.91	0.99	17.35
		0.10 1.	00 10.00	100.00		
			RR (95% Crl)			

Figure A5
Outcome: Any Stent Thrombosis

Treatment	Control	Treatment	Control	Rate Ratio	95%	Crl
BMS (Ref)						
	Sirolimus	-	-	0.57	0.25	1.14
	Paclitaxel	-	<u> </u>	0.75	0.36	1.60
	Everolimus		_	0.52	0.15	1.37
	Zotarolimus		•	2.78	0.59	16.26
Sirolimus (Ref)						
	Paclitaxel	_	—	1.33	0.70	2.58
	Everolimus	-		0.89	0.36	2.17
	Zotarolimus		-	4.89	1.31	26.50
Paclitaxel (Ref)						
	Everolimus			0.69	0.25	1.55
	Zotarolimus	-	•	3.61	0.96	19.56
Everolimus (Ref)						
	Zotarolimus			5.52	1.23	36.43
		0.10 1.0	00 10.00	100.00		
			RR (95% Crl)			

Figure A6
Outcome: Def/Prob Stent Thrombosis

Treatment	Control	Treatment	Control	Rate Ratio	95%	Crl
BMS (Ref)						
	Sirolimus		_	0.43	0.18	0.91
	Paclitaxel	-		0.66	0.29	1.67
	Everolimus	-	_	0.38	0.10	1.37
	Zotarolimus		*	4.32	0.75	37.07
Sirolimus (Re	ef)					
	Paclitaxel			1.55	0.81	3.71
	Everolimus		•	0.89	0.29	2.83
	Zotarolimus		-	9.92	1.92	82.43
Paclitaxel (Re	ef)					
	Everolimus		_	0.58	0.18	1.59
	Zotarolimus		-	6.28	1.32	47.14
Everolimus (F	Ref)					
	Zotarolimus		-	11.13	1.83	111.20
		0.10	1.00 10.00	100.00		
			RR (95% Crl)			

Figure A7.
Outcome: Def Stent Thrombosis

Treatment	Control	Treatment	Control	Rate Ratio	95%	Crl
BMS (Ref)						
	Sirolimus	-	_	0.25	0.07	0.68
	Paclitaxel		•	0.60	0.20	1.57
	Everolimus	-	_	0.22	0.02	0.97
	Zotarolimus	_	*	2.07	0.33	24.86
Sirolimus (Re	ef)					
	Paclitaxel			2.39	1.07	6.69
	Everolimus			0.85	0.14	3.35
	Zotarolimus		-	8.67	1.71	75.44
Paclitaxel (Re	ef)					
	Everolimus			0.37	0.06	1.14
	Zotarolimus		+	- 3.66	0.71	31.57
Everolimus (F	Ref)					
	Zotarolimus		-	10.67	1.51	150.60
		0.01 0.10	1.00 10.00	100.00		
		RR	(95% Crl)			

Figure A8.
Outcome: TVR

Treatment	Control	Treatment	Control	Odds Ratio	95%	Crl
BMS (Ref)						
	Sirolimus	-		0.38	0.30	0.48
	Paclitaxel	-		0.47	0.37	0.60
	Everolimus			0.33	0.20	0.46
	Zotarolimus		-	0.62	0.42	0.91
	Zotarolimus-R	-	-	0.51	0.25	0.93
Sirolimus (Ref)						
	Paclitaxel		-	1.25	0.99	1.55
	Everolimus	_	+	0.86	0.57	1.14
	Zotarolimus		_	1.66	1.13	2.39
	Zotarolimus-R	_	-	1.33	0.68	2.35
Paclitaxel (Ref)						
	Everolimus	-	-	0.69	0.45	0.94
	Zotarolimus		 	1.33	0.92	1.94
	Zotarolimus-R	· ·		1.08	0.55	1.91
Everolimus (Ref)						
	Zotarolimus			1.91	1.22	3.39
	Zotarolimus-R		—	1.54	0.95	2.63
Zotarolimus (Ref)						
	Zotarolimus-R			0.82	0.37	1.53
	0.10		1.00	10.00		
		RR	(95% Crl)			

Figure B1.




Figure B2.




Figure B3.




Figure B4.




Figure B5.




Figure B6.




Figure B7.

